NYU Langone开始用转基因器官进行猪肾移植试验,以缓解美国器官短缺问题。 NYU Langone begins pig kidney transplant trial with genetically modified organs to ease U.S. organ shortage.

在NYU Langone Health公司,开始对人体猪肾移植进行临床试验试验,由联合治疗机构实施第一个成功程序。 A clinical trial testing pig kidney transplants in humans has begun at NYU Langone Health, with United Therapeutics performing the first successful procedure. 该试验涉及多达50名病人,使用转基因猪肾,并作了10次编辑,以减少排斥。 The trial, involving up to 50 patients, uses genetically modified pig kidneys with 10 edits to reduce rejection. 早期的实验移植持续了271天,为解决美国器官短缺问题带来了希望,那里有10万多人等待移植。 Earlier experimental transplants lasted up to 271 days, offering hope for addressing the U.S. organ shortage, where over 100,000 people await transplants. 如果猪肾衰竭,病人可以恢复透析,从而提供一个安全网。 Patients can return to dialysis if the pig kidney fails, providing a safety net. FDA 在之前的同情用例之后批准了该试验。 The FDA approved the trial following prior compassionate-use cases. 第二个美国公司eGenesis正在准备启动自己的审判。 A second U.S. company, eGenesis, is preparing to launch its own trial.